RAMAT GAN, Israel--(BUSINESS WIRE)--Obecure has completed enrollment of patients for its Phase II clinical trial to evaluate the efficacy of the company’s OBE101 drug candidate for weight loss in obese patients. The double-blinded, placebo-controlled dose-ranging study is being conducted at 20 medical sites across the U.S.
